About ElmediX
ElmediX is a company based in Leuven (Belgium) founded in 2015 by John-Paul Bogers and Johan Van den Bossche. ElmediX has raised $4.53 million across 1 funding round. The company has 12 employees as of December 31, 2022. ElmediX offers products and services including Thermal Therapy. ElmediX operates in a competitive market with competitors including Sensius, MagForce, Siva Therapeutics, NeoTherma Oncology and MagHeals, among others.
- Headquarter Leuven, Belgium
- Employees 12 as on 31 Dec, 2022
- Founders John-Paul Bogers, Johan Van den Bossche
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Elmedix
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.53 M (USD)
in 1 rounds
-
Latest Funding Round
$4.53 M (USD), Series A
Jan 25, 2022
-
Investors
Not available
-
Employee Count
12
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ElmediX
ElmediX offers a comprehensive portfolio of products and services, including Thermal Therapy.
Heat-based method to target and destroy cancer cells effectively.
People of ElmediX
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ElmediX
ElmediX has successfully raised a total of $4.53M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.53 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by ElmediX
Investment portfolio details for ElmediX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ElmediX
Detailed financials for ElmediX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Elmedix Comparisons
Peer comparison for ElmediX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ElmediX
ElmediX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sensius, MagForce, Siva Therapeutics, NeoTherma Oncology and MagHeals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a hyperthermia system for cancer treatment. This system uses thermotherapy, a controlled heating process, to target tumors while preserving surrounding healthy tissue. The technology is designed to be integrated with existing radiotherapy workflows, offering improved clinical outcomes and enhanced quality of life for patients. The system is currently in development, with prototypes undergoing clinical trials. Future applications are planned for various cancer types.
|
|
| Locked | Locked | Locked |
Medical devices utilizing magnetic hyperthermia for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Gold nanoparticle hyperthermia technology for cancer therapy is developed.
|
|
| Locked | Locked | Locked |
Deep solid tumors are treated with radio frequency thermal therapy.
|
|
| Locked | Locked | Locked |
Magnetic hyperthermia devices for non-invasive cancer treatment are provided.
|
Detailed competitors of ElmediX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Elmedix
Complete news archive for ElmediX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ElmediX
ElmediX was founded in 2015 and raised its 1st funding round 7 years after it was founded.
ElmediX is headquartered in Leuven, Belgium. It is registered at Leuven, Flemish Brabant, Belgium.
John-Paul Bogers is the current CEO of ElmediX. They have also founded this company.
ElmediX is a funded company, having raised a total of $4.53M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at ElmediX is 12.
ElmediX was founded in 2015 in Leuven, Belgium, as a medical technology company focused on oncology. A specialized device is developed to deliver heat to tumors, thereby enhancing their sensitivity to chemotherapy or radiotherapy via physiological mechanisms. Operations center on device innovation and clinical application for pancreatic cancer treatment, with leadership provided by co-founders in CEO and CTO roles.
ElmediX's top competitors include Sensius, MagHeals and Siva Therapeutics.
ElmediX offers Thermal Therapy.